NASDAQ · Biotechnology

MannKind Corporation (MNKD) Stock

$4.06 -1.82% NASDAQ: MNKD Healthcare

MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S.

Valuation

MetricValue
Price$4.06
Market Cap$1.25B
P/E Ratio-53.43
P/B Ratio-21.51
P/S Ratio3.54
EPS (TTM)$0.02
52-Week High$6.51
52-Week Low$2.23
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE45.59%
ROA-3.21%
ROCE2.20%
Gross Margin75.96%
Operating Margin3.71%
Net Margin-6.63%
Debt/Equity-7.38
Current Ratio1.71

Annual Financials (USD)

Metric20212022202320242025
Revenue$75.0M$100.0M$199.0M$286.0M$349.0M
Operating Profit$-47.0M$-64.0M$9.0M$73.0M$39.0M
Net Profit$-81.0M$-87.0M$-12.0M$28.0M$6.0M
EPS$-0.37$-0.44$-0.04$0.10$0.02
Op Margin-62.3%-64.3%4.4%25.4%11.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$321.0M$295.0M$475.0M$394.0M$792.0M
Total Liabilities$531.0M$546.0M$721.0M$473.0M$843.0M
Cash$124.0M$70.0M$238.0M$46.0M$75.0M
Borrowings$289.0M$288.0M$273.0M$48.0M$473.0M

Latest News

MannKind Corporation (MNKD) Up 20% Since Afrezza FDA Approval Insider Monkey · Jul 9, 2026 MannKind (MNKD) Receives a Grant from Breakthrough T1D Insider Monkey · Jul 3, 2026 Is MannKind Corporation (MNKD) A Good Stock To Buy Now? Insider Monkey · Jun 29, 2026 MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D GlobeNewswire · Jun 23, 2026 Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story” Insider Monkey · Jun 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-62.0M$-81.0M$34.0M$43.0M$18.0M
Investing Cash Flow$-163.0M$-3.0M$-44.0M$-106.0M$-309.0M
Financing Cash Flow$-13.0M$0$137.0M$2.0M$-9.0M
Net Cash Flow$57.0M$-54.0M$169.0M$-191.0M$29.0M
Free Cash Flow$-73.0M$-88.0M$-8.0M$33.0M$14.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.30
EV / EBITDA32.37
FCF Yield1.12%
Quick Ratio1.50
Interest Coverage2.79
Return 1Y-5.12%
Return 3Y-12.19%
Return 5Y-13.00%

Ownership

Insiders Held1.55%
Institutions Held59.23%
Institutions Float Held60.16%
Institutional HolderSharesReport Date
Blackrock Inc.28,600,9982026-03-31
State Street Corporation18,683,4832026-03-31
Vanguard Capital Management LLC12,891,0662026-03-31
UBS Group AG8,255,4302026-03-31
Geode Capital Management, LLC7,505,1472026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABCL $6.93 +6.13% -5.91 $2.12B 0.00%
AUPH $15.00 -1.19% 7.46 $1.93B 0.00%
BHVN $14.07 +3.19% -6.11 $2.12B 0.00%
CLDX $35.80 +0.63% -7.84 $2.38B 0.00%
HRMY $38.24 -1.39% 11.23 $2.21B 0.00%

About MannKind Corporation

MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.

MannKind Corporation is led by CEO Michael E. Castagna, employs 403 people, headquartered in US, publicly traded since 2004.

MannKind Corporation (MNKD) stock trades at $4.06 with a market capitalization of $1.25B. The stock is valued at a price-to-earnings (P/E) ratio of -53.43, price-to-book of -21.51, price-to-sales of 3.54. Over the past 52 weeks the stock has ranged between $2.23 and $6.51, and currently trades 37.6% below its 52-week high.

On profitability, MannKind Corporation generates a return on equity (ROE) of 45.59% — well above the market average, a sign of a high-quality business, return on capital employed of 2.20%, an operating margin of 3.71%, a net profit margin of -6.63%.

Official website: www.mannkindcorp.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides